Testing A New Experimental Drug To Raise Good Cholesterol Level

Testing A New Experimental Drug To Raise Good Cholesterol Level.

An exploratory soporific that raises HDL, or "good," cholesterol seems to have passed an prime hurdle by proving safe in preliminary trials. Although the trial was primarily designed to appear at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual intersection in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and weaken LDL, HDL's evil twin, almost in half for more. "We saw very encouraging reductions in clinical events," said Dr Christopher Cannon, exemplar author of the study, which also appears in the Nov 18, 2010 promulgation of the New England Journal of Medicine.

A big study to verify the results would take four to five years to complete so the drug is still years away from market who is a cardiologist with Brigham and Women's Hospital in Boston. Other experts are intrigued by the findings, but note that the examine is still in very old stages full article. "There are a lot of people in the prevention/lipid field that are simultaneously excited and leery," said Dr Howard Weintraub, clinical chief of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.

Added Dr John C LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very prior but it's impressive because the persist drug out of the barrel of this type was not a success. This looks for example a better drug, but it's not definitive by any means. Don't take this to the bank".

LaRosa was referring to torcetrapib, which, peer anacetrapib, belongs to the class of drugs known as cholesterol ester give protein (CETP) inhibitors. A large trial on torcetrapib was killed after investigators found an increased hazard of death and other cardiovascular outcomes. "I would be more excited about anacetrapib if I hadn't seen what happened to its cousin torcetrapib. Torcetrapib raised HDL astoundingly but that was root and branch neutralized by the multiply in cardiovascular events".

In the new trial, anacetrapib actually showed a tendency toward fewer cardiovascular problems and fewer angioplasty or go procedures, although the study only lasted 18 months. It also didn't fruit in the blood pressure increases that helped doom torcetrapib.

To assess the safeness of the trial, investigators randomly chose 1623 adults with coronary heart disease who were taking cholesterol-lowering statins to suffer either anacetrapib or a placebo for 18 months. At the end of six months, LDL cholesterol was diminished 81 milligrams per deciliter (mg/dl) of blood to 45 mg/dl, a reduction of about 40 percent. In the placebo group, LDL levels only declined from 82 mg/dl to 77 mg/dl.

Meanwhile, HDL levels increased from 41 mg/dl of blood to 101 mg/dl in the curing arm, versus a meagre escalation from 40 mg/dl to 46 mg/dl in the placebo group. "We have 94 percent faith that this drug doesn't have the harmful efficacy that torcetrapib had, but we didn't prove a reduction in events," said Brigham and Women's Cannon. "That will be the course of a larger study".

Such a study is in the works. Dr Neil Coplan, manager of clinical cardiology at Lenox Hill Hospital in New York City, stressed that this was a "safety trial, not a exploratory which is saying in any way that people should take these medications nor are the drugs approved". Still "the whirl demonstrated safety and it demonstrated a tremendous effect on altering the lipid diagram in a good direction. It's very promising but, as the authors note themselves, it's a first step".

Experts are still divided as to whether raising HDL levels will indeed result in any meaningful improvements in clinical outcomes. "Currently, we're not convinced that manipulation of HDL matters, though certainly it's promising," said Weintraub, who added that results should be at one's disposal extent soon from other trials exploring the issue. "The experience that LDL was also reduced also makes it promising. We've never been able to satisfactorily demonstrate that raising HDL literally changes risk" additional reading. The only drug currently available to raise HDL is nyacin.

tag : torcetrapib cholesterol anacetrapib trial study clinical cardiovascular blood safety

Post a comment

Private comment



Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Форма поиска
RSS ссылка
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья